Breaking News

In Big Win For 340B Hospitals, CMS Will Reverse Massive Drug Reimbursement Cut for 2023 and Seeks Input on Potential Remedies for Prior Years

CMS announced late today that they are reversing significant Medicare cuts to 340B hospitals.

The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.

Read More »

Breaking News

In Important Ruling, Federal Appeals Court Says Health Center May Challenge 340B Patient Definition’s Legality

A federal appeals court says South Carolina health center Genesis Healthcare has the right to challenge the 340B patient definition's legality in a lower federal court.

A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court.

Please Login or Become

Read More »

Breaking News

Bausch Health Announces 340B Contract Pharmacy Restrictions on All Covered Entities

Bausch Health has imposed conditions on 340B pricing when all covered entity types—hospitals and grantees alike—use contract pharmacies.

Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Breaking News

U.S. Supreme Court Strikes Down Medicare Part B Drug Payment Cuts for 340B Hospitals in 2018 and 2019

The U.S. Supreme Court today struck down deep Medicare Part B drug reimbursement cuts for many 340B hospitals during 2018 and 2019. The decision does not affect continuation of the cuts in 2020 through this year, however.

The U.S. Supreme Court ruled unanimously this morning that the federal government unlawfully slashed Medicare Part B drug reimbursement for many 340B hospitals by almost 30 percent during 2018 and 2019.

Please Login or

Read More »

Breaking News

HRSA Sends Merck 340B Contract Pharmacy Cease and Desist Letter, Agency’s First in Seven Months

HRSA told Merck today the company's conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop or Merck could face civil monetary penalties.

The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each

Read More »

Breaking News

HRSA Picks Federal HIV/AIDS Policy Specialist Emeka Egwim To Be its Next 340B Program Director

PHS Lt. Cmdr. Emeka Edwim is the new Director of HRSA's Office of Pharmacy Affairs, the HRSA unit that runs the 340B drug pricing program.

Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.

Please Login or Become a Paid Subscriber

Read More »

Breaking News

Federal Judge Vacates HRSA’s Finding that AstraZeneca’s 340B Contract Pharmacy Policy Is Illegal

A federal district judge today struck down and vacated HRSA's May 2021 finding that AstraZeneca's 340B contract pharmacy policy violates the 340B statute.

A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities uses contract pharmacies violates the 340B statute.

Please Login

Read More »

Breaking News

Hospital Group Leader Says “We’re Prepared to Go” in Direction of Federal 340B Contract Pharmacy Legislation

If the path to solving the 340B contract pharmacy dispute runs through Congress, "we're prepared to go in that direction,” 340B Health President and CEO Maureen Testoni said today.

For the first time since the 340B contract pharmacy impasse started over a year and half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal legislative

Read More »

Breaking News

BMS Clamps Down on 340B Contract Pharmacy for Most of its Drugs but Expands 340B Access to its Controversial Myeloma Meds Program

BMS yesterday imposed restrictions on 340B pricing on most of its covered outpatient drugs, while liberalizing its policy on access to 340B pricing on its expensive cancer drugs Revlimid, Pomalyst, and Thalomid.

Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.

Please Login or Become a Paid

Read More »

Breaking News

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report